Silence Therapeutics

About us

Our technology

We have developed proprietary stabilizing chemistries to improve the robustness of siRNA sequences, together with advanced delivery systems that enable us to specifically target relevant cell types. This results in potent and highly specific product candidates.

Investors

Find out more about our investment case, share price, corporate governance and related information. Download our latest reports and announcements.

Investors

Investment Case

Silence has been a pioneer in the RNAi field for over 18 years. Through the efforts of our skilled researchers and scientists, we have established an innovative platform with broad intellectual property protection. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron loading anemias and complement-mediated disorders. 

 

Results, reports & presentations
Annual Report and Accounts 2019 Cover.PNG

Please download our 2019 Annual Report here

2019 Annual Report

Full Year Results 2019

Half Year Results 2019

Investors

Results, reports and presentations 

Find out more about our investment case, share price, corporate governance and related information. 

Download our latest reports and announcements.

Read more